Use our timeline to chart all vaccine bond issuances in capital markets around the world since their launch in London in 2006.
In July 2019, IFFIm raised NOK 600 million (US$ 65.7 million equivalent), marking its 35th issuance and its first bond in Norwegian krone. The transaction, jointly managed by Skandinaviska Enskilda Banken (SEB) and the Toronto-Dominion Bank, will frontload a pledge from the Government of Norway to Gavi in support of research and development of new vaccines by the Coalition for Epidemic Preparedness Innovation (CEPI). Japan’s Dai-ichi Life is a major purchaser and IFFIm’s first institutional investor in Japan, joined by two Norwegian institutions, Kommunalbanken (KBN) and Norwegian pension fund MP.
In April 2019, IFFIm raised US$ 50 million in a private placement of 3-year Sukuk that complies with Islamic financing principles, was issued by IFFIm, with IsDB as the sole investor. The First Abu Dhabi Bank (FAB) acted as placement agent on the transaction.
IFFIm returns again to the international US dollar benchmark market, raising US$ 300 million in a transaction jointly led by Citi, Crédit Agricole and Goldman Sachs International. This re-establishes IFFIm as regular borrower in the market following its US$ 500 million 3-year floating rate note issued in October 2016.
IFFIm’s return to the international US$ benchmark market, raising US$ 500 million in a transaction jointly led by Citi, Deutsche Bank and J.P. Morgan. It is IFFIm’s second floating rate offer and its fifth benchmark since 2006.
IFFIm issued a second sukuk, raising US$ 200 million with a 3-year socially responsible investment that complies with Islamic law. The sukuk was oversubscribed, maturing on 29 September 2018, carrying a quarterly coupon of +14 basis points over 3-month USD LIBOR.
IFFIm entered the sukuk market for the first time, raising US$ 500 million with a 3-year socially responsible investment that complies with Islamic law. The sukuk was oversubscribed, maturing on 4 December 2017, carrying a quarterly coupon of +15 basis points over 3-month USD LIBOR.
IFFIm issues its largest financing since its inaugural benchmark, raising US$ 700 million in a transaction jointly led by Daiwa Securities Group and Deutsche Bank. It is IFFIm’s first floating rate offer, and its first benchmark since 2010 (fourth overall).
Daiwa Securities Group sponsors its fifth highly successful issuance of IFFIm vaccine bonds, raising US$ 139 million with 5-year notes denominated in Turkish lira and South African rand. The total amount arranged by Daiwa now is about US$ 1.35 billion equivalent.
IFFIm makes a strong return to the capital markets, raising the equivalent of US$ 137.2 million for Gavi programmes with two uridashi retail bond offerings. The first was arranged by HSBC and raised US$ 98.4 million. Investors were offered a 3-year fixed-rate South African rand-denominated bond, a 4.5-year fixed-rate Australian dollar-denominated bond and a 15-year South African rand-denominated deep-discount bond. The second uridashi was a 5-year Australian dollar-denominated bond underwritten by J.P. Morgan that raised US$ 38.76 million.
In September 2011, IFFIm completed its first J.P. Morgan-arranged issue of vaccine bonds, raising the equivalent of US$ 169.4 million for Gavi programmes. The issuance included tranches in three currencies, comprising a 5-year South African rand tranche in the amount of ZAR 650 million (US$ 91 million equivalent); a 3-year Brazilian real tranche in the amount of BRL 105 million (US$ 66 million equivalent); and a 4-year Australian dollar tranche in the amount of AUD 12 million (US$ 12.4 million equivalent).
In March 2011, IFFIm completed the fourth issue of IFFIm's vaccine bonds arranged by Daiwa, raising BRL 371 million (US$ 225 million). The previous, highly successful issues were completed in March 2008, February 2009 and March 2010. The total amount of IFFIm's vaccine bonds arranged by Daiwa is now over US$ 1 billion equivalent.
In November, 2010, IFFIm's inaugural Kangaroo bond was successfully completed. The A$ 400 million (US$ 395 million), five-year bond issue was lead managed by the Commonwealth Bank of Australia and RBC Capital Markets. The notes were placed globally, across a broad range of over 20 investors.
In October 2010, IFFIm raised A$ 35 million (US$ 34 million) in a private placement of five-year Eurobonds arranged for IFFIm by the TD Securities.
In June 2010, IFFIm raised US$ 101 million equivalent in three uridashi offerings in Japan. The multi-tranche transaction includes Australian dollar and South African rand denominated bonds and the first IFFIm bond denominated in Brazilian real and settled in Japanese Yen. This offering was arranged by HSBC Securities (Japan).
In March 2010, IFFIm raised ZAR 2.5 billion (US$ 320.5 million) in a three year uridashi offering in Japan. This was the third issue arranged for IFFIm by the Daiwa Securities Group, and was IFFIm's largest South African rand denominated issuance to date.
In June, 2009, a multi-tranche uridashi offering of IFFIm vaccine bonds, arranged by HSBC Securities (Japan), was sold through a group of 19 securities distributors and offered to Japanese investors online. The total amount of the offering was approximately US$ 130 million and was composed of three tranches: (i) a four-year Australian dollar fixed rate tranche; (ii) a four-year South African rand fixed rate tranche, and (iii) a 15 year South African rand deep discount tranche.
IFFIm issued its first bonds in the sterling market in May 2009. The two tranche transaction raised an aggregate £266 million (approximately US$ 400 million) and was split between a £250 million fixed rate tranche for institutional investors and a £16,227,290 zero coupon tranche for retail investors. The institutional tranche was lead managed by HSBC and Royal Bank of Scotland. The retail tranche was packaged as the HSBC Vaccine Investment Plan and HSBC Individual Savings Account (ISA).
On 26 May 2009, IFFIm completed a multi-tranche uridashi offering in Japan. The total amount of the offering was US$ 142.9 million made up of two tranches, one in US dollars and the other in Australian dollars. Both tranches are due 25 May 2012. The offering was arranged by Mitsubishi UFJ Securities Co., Ltd.
An offering to Japanese retail investors in February 2009 raised US$ 429 million equivalent. Investors were given the opportunity and choice of investing in "vaccine bonds" denominated in three currencies: South African rand, New Zealand dollars and Australian dollars. The currencies were selected based on investor demand. This offering for the Japanese market was arranged by Daiwa Securities SMBC Co. Ltd., the wholesale securities firm under Daiwa Securities Group, and distributed by Daiwa Securities to Japanese investors.
Japanese investors welcomed the launch in March 2008 of IFFIm's debut offering in the Japanese retail market, a R 1.7 billion (US$ 223 million) two year uridashi issue. The "vaccine bonds" were arranged by Daiwa Securities SMBC Co. Ltd., the wholesale securities firm under Daiwa Securities Group, and distributed by Daiwa Securities to Japanese investors.
IFFIm's inaugural bonds were issued in London on 14 November 2006 and raised US$ 1 billion. The bonds were priced comparably to other sovereign/supranational issuers and were bought by a broad range of investors - both geographically and by investor type - including several central banks, pension funds, fund managers, and insurance companies. Deutsche Bank and Goldman Sachs lead-managed this inaugural bond issue.
*Individuals who have supported the IFFIm initiative include His Holiness Pope Benedict XVI; Her Majesty Queen Rania Al-Abdullah of Jordan; Cardinal Renato Raffaele Martino; Archbishop of Canterbury, Dr Rowan Williams; Chief Rabbi, Dr Jonathan Sacks; Iqbal Khan of the Muslim Council of Britain; Ramesh Khalidi of the Hindu Forum; Indrajit Singh OBE of the Sikh Council of Britain as well as Bono and Bob Geldof.